Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 and expanded imaging study of tozuleristide in patients with pediatric primary central nervous system tumors.

Journal of neurosurgery. Pediatrics·2025
Same author

A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary clinical trials communications·2021
Same author

A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposure.

Science translational medicine·2020
Same author

Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.

Neurosurgery·2019
Same author

Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide.

Archives of pathology & laboratory medicine·2018
Same author

Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent.

International journal of toxicology·2017

Related Experiment Video

Updated: Jun 17, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon lambda as a potential new therapeutic for hepatitis C.

Dennis M Miller1, Kevin M Klucher, Jeremy A Freeman

  • 1ZymoGenetics, Inc., Seattle, Washington 98102, USA. millerd@zgi.com

Annals of the New York Academy of Sciences
|January 16, 2010
PubMed
Summary

Interferon lambdas (IFN-lambda), a Type III interferon, show antiviral activity with fewer side effects than Type I interferons. PEGylated IFN-lambda (PEG-rIL-29) demonstrated safety and efficacy in hepatitis C patients.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Immunology
  • Virology
  • Hepatology

Background:

  • Interferon lambdas (IFN-lambda) are Type III interferons with antiviral gene-inducing properties.
  • IFN-lambda signals via a distinct receptor, unlike Type I interferons (IFN-alpha).
  • The cell-specific IFN-lambda receptor suggests potentially fewer systemic side effects compared to IFN-alpha.

Purpose of the Study:

  • To evaluate the safety and efficacy of PEGylated interferon lambda (PEG-rIL-29) as a therapeutic agent.
  • To assess the potential for reduced hematologic toxicities associated with PEG-rIL-29 compared to traditional interferons.
  • To explore the antiviral effects of PEG-rIL-29 in patients with hepatitis C.

Main Methods:

  • Preclinical animal studies to assess tolerability and toxicity of PEG-rIL-29.
  • Animal models evaluated for hematologic toxicity.
  • Early-phase clinical trials in hepatitis C patients to determine safety and antiviral activity.

Main Results:

  • PEG-rIL-29 was well tolerated in animal studies.
  • No hematologic toxicity was observed in preclinical animal models treated with PEG-rIL-29.
  • Clinical studies showed PEG-rIL-29 exerted antiviral effects in hepatitis C patients without causing hematologic toxicity.

Conclusions:

  • PEG-rIL-29 demonstrates a favorable safety profile, particularly regarding hematologic toxicity.
  • Preclinical and early clinical data support PEG-rIL-29 as a promising therapeutic candidate for hepatitis C.
  • The distinct receptor complex of IFN-lambda may contribute to its improved side effect profile.